

Clinical trial results:

A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Severe Myasthenia Gravis

Summary

EudraCT number	2016-002698-36
Trial protocol	DE BE ES CZ DK
Global end of trial date	06 August 2018
Results information	
Result version number	v2 (current)
This version publication date	19 August 2021
First version publication date	05 September 2019
Version creation reason	Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review

Trial information

Trial identification		
Sponsor protocol code	MG 0002	
Additional study identifiers		
ISRCTN number	-	
ClinicalTrials.gov id (NCT number)	NCT03052751	
WHO universal trial number (UTN)	-	

Notes:

Sponsors	
Sponsor organisation name	UCB Biopharma SPRL
Sponsor organisation address	Allée de la Recherche 60, Brussels, Belgium, 1070
Public contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ ucb.com
Scientific contact	Clin Trial Reg & Results Disclosure, UCB BIOSCIENCES GmbH, clinicaltrials@ ucb.com

Notes:

Paediatric regulatory details	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage	
Analysis stage	Final
Date of interim/final analysis	04 September 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 August 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Evaluate the clinical efficacy of UCB7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.

Protection of trial subjects:

During the conduct of the study all subjects were closely monitored. If required, subjects received rescue therapy and were withdrawn from treatment. Subjects were then monitored during the 8 weeks observation period until lab levels returned to normal.

Background therapy:

Background therapy as permitted in the protocol.

Evidence for comparator:

Not Applicable

Actual start date of recruitment	15 May 2017
Long term follow-up planned	No
Independent data monitoring committee	No
(IDMC) involvement?	

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled

EEA total number of subjects

Country: Number of subjects enrolled	Belgium: 10
Country: Number of subjects enrolled	Canada: 11
Country: Number of subjects enrolled	Czechia: 2
Country: Number of subjects enrolled	Denmark: 7
Country: Number of subjects enrolled	Germany: 3

23

Spain: 1

Country: Number of subjects enrolled	United States:
Worldwide total number of subjects	43

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

9

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	32
From 65 to 84 years	11
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study started to enroll patients in May 2017 and concluded in August 2018.

Pre-assignment

Screening details:

The Participant Flow refers to the Randomized Set (RS) which consisted of all participants randomized into the study at the first randomization visit.

Period 1	
Period 1 title	Dosing Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Assessor, Carer, Investigator, Subject

Blinding implementation details:

For reporting of this study, due to limitations of the drop-down list for blinding, the wording Double Blind was utilized instead of Investigator- and Subject-Blind.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received 3 doses of placebo in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg).

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	PBO
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Subcutaneous use
	•

Dosage and administration details:

Placebo was administered in Dosing Period 1.

Arm title	UCB7665 (7 mg/kg)
-----------	-------------------

Arm description:

Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg).

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Number of subjects in period 1	Placebo	UCB7665 (7 mg/kg)
Started	22	21
Completed Period 1	22	21
Completed Period 1 and started Period 2	22	20
Completed	22	20
Not completed	0	1
Adverse event, non-fatal	-	1

Period 2	
Period 2 title	Dosing Period 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Assessor, Carer, Investigator, Subject
Blinding implementation details:	
For reporting of this study, due to limitation was utilized instead of Investigator- and	tions of the drop-down list for blinding, the wording Double Blind Subject-Blind.
Arms	
Are arms mutually exclusive?	Yes
Arm title	Placebo - UCB7665 (7 mg/kg)
Arm description:	
	les of placebo at weekly intervals in Dosing Period 1 were then 87665 (7 mg/kg) at weekly intervals in Dosing Period 2.
Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use
Dosage and administration details:	
UCB7665 was administered in 2 differen	t dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2.
Arm title	Placebo - UCB7665 (4 mg/kg)
Arm description:	
	es of placebo at weekly intervals in Dosing Period 1 were then 87665 (4 mg/kg) at weekly intervals in Dosing Period 2.
Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use
Dosage and administration details:	

Arm title

UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)

Arm description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

UCB7665 was administered in 2 different dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2.

Arm title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)

Arm description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Number of subjects in period 2	Placebo - UCB7665 (7 mg/kg)	Placebo - UCB7665 (4 mg/kg)	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)
			mg/kg/
Started	11	11	10
Completed	8	11	10
Not completed	3	0	0
Adverse event, non-fatal	3	-	-

Number of subjects in period 2	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Started	10
Completed	10
Not completed	0
Adverse event, non-fatal	-

Period 3 Period 3 title Observation Period No Is this the baseline period? Allocation method Randomised - controlled Blinding used Double blind Roles blinded Assessor, Carer, Investigator, Subject Blinding implementation details: For reporting of this study, due to limitations of the drop-down list for blinding, the wording Double Blind was utilized instead of Investigator- and Subject-Blind. **Arms** Are arms mutually exclusive? No Arm title Placebo Arm description: Participants received 3 doses of placebo in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Placebo Arm type Investigational medicinal product name Placebo Investigational medicinal product code PBO Other name Pharmaceutical forms Solution for infusion Routes of administration Subcutaneous use Dosage and administration details: Placebo was administered in Dosing Period 1. Arm title UCB7665 (7 mg/kg) Arm description: Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Experimental Arm type Investigational medicinal product name Rozanolixizumab Investigational medicinal product code UCB7665 Other name Powder for solution for infusion Pharmaceutical forms Routes of administration Subcutaneous use Dosage and administration details: UCB7665 was administered in 2 different dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2. **Arm title** Placebo - UCB7665 (7 mg/kg) Arm description: Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2. Experimental Arm type Rozanolixizumab Investigational medicinal product name Investigational medicinal product code UCB7665 Other name Pharmaceutical forms Powder for solution for infusion Routes of administration Subcutaneous use

Dosage and administration details:

UCB7665 was administered in 2 different dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2.

Arm title Pla	acebo - UCB7665 (4 mg/kg)
---------------	---------------------------

Arm description:

Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

UCB7665 was administered in 2 different dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2.

Arm title	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)
-----------	---------------------------------------

Arm description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

UCB7665 was administered in 2 different dosages (7 mg/kg and 4 mg/kg) in Dosing Period 1 and 2.

Arm title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)

Arm description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2.

Arm type	Experimental
Investigational medicinal product name	Rozanolixizumab
Investigational medicinal product code	UCB7665
Other name	
Pharmaceutical forms	Powder for solution for infusion
Routes of administration	Subcutaneous use

Dosage and administration details:

Number of subjects in period 3	Placebo	UCB7665 (7 mg/kg)	Placebo - UCB7665 (7 mg/kg)
Started	22	21	11
Completed	22	21	11
Not completed	0	0	0
Adverse event, non-fatal	-	-	-

Number of subjects in period 3	Placebo - UCB7665 (4 mg/kg)	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Started	11	10	10
Completed	11	9	10
Not completed	0	1	0
Adverse event, non-fatal	-	1	-

Baseline characteristics

Reporting groups

Reporting group title	Placebo

Reporting group description:

Participants received 3 doses of placebo in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg).

Reporting group title UCB7665 (7 mg/kg)

Reporting group description:

Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg).

Reporting group values	Placebo	UCB7665 (7 mg/kg)	Total
Number of subjects	22	21	43
Age categorical			
Units: Subjects			
< = 18 years	0	0	0
Between 18 and 65 years	14	18	32
> = 65 years	8	3	11
Age continuous			
Units: years			
arithmetic mean	53.3	50.5	
standard deviation	± 15.7	± 14.7	-
Gender categorical			
Units: Subjects			
Male	8	8	16
Female	14	13	27

End points

End points reporting groups Reporting group title	Placebo
Reporting group description:	riaceno
	in Dosing Period 1 and then were re-randomized into Dosing
Reporting group title	UCB7665 (7 mg/kg)
Reporting group description:	[
	5 (7 mg/kg) in Dosing Period 1 and then were re-randomized of UCB7665 (7 mg/kg or 4 mg/kg).
Reporting group title	Placebo - UCB7665 (7 mg/kg)
Reporting group description:	
	ses of placebo at weekly intervals in Dosing Period 1 were then 37665 (7 mg/kg) at weekly intervals in Dosing Period 2.
Reporting group title	Placebo - UCB7665 (4 mg/kg)
Reporting group description:	
	ses of placebo at weekly intervals in Dosing Period 1 were then 37665 (4 mg/kg) at weekly intervals in Dosing Period 2.
Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)
Reporting group description:	
	ses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period obses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period
Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Reporting group description:	
	ses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period obses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period
Reporting group title	Placebo
Reporting group description:	
Participants received 3 doses of placebo Period 2 to receive 3 doses of UCB7665	in Dosing Period 1 and then were re-randomized into Dosing (7 mg/kg or 4 mg/kg).
Reporting group title	UCB7665 (7 mg/kg)
Reporting group description:	
Participants received 3 doses of UCB766 into Dosing Period 2 to receive 3 doses of	5 (7 mg/kg) in Dosing Period 1 and then were re-randomized of UCB7665 (7 mg/kg or 4 mg/kg).
Reporting group title	Placebo - UCB7665 (7 mg/kg)
Reporting group description:	
re-randomized to receive 3 doses of UCE	ses of placebo at weekly intervals in Dosing Period 1 were then 37665 (7 mg/kg) at weekly intervals in Dosing Period 2.
Reporting group title	Placebo - UCB7665 (4 mg/kg)
Reporting group description:	
	ses of placebo at weekly intervals in Dosing Period 1 were then 37665 (4 mg/kg) at weekly intervals in Dosing Period 2.
Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)
Reporting group description:	
	ses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Periodoses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period
Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Reporting group description:	
	ses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Periodoses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period

2.

Subject analysis set title	Placebo (FAS)
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received 3 doses of placebo in Dosing Period 1. Participants formed the Full Analysis Set (FAS) which consisted of all participants in the Safety Set (SS) who had a Baseline and at least 1 post-Baseline QMG measurement during Dosing Period 1 (up to and including Visit 9, ie, Day 29).

Subject analysis set title	UCB7665 (7 mg/kg) (FAS)
Subject analysis set type	Full analysis

Subject analysis set description:

Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1. Participants formed the Full Analysis Set (FAS) which consisted of all participants in the Safety Set (SS) who had a Baseline and at least 1 post-Baseline QMG measurement during Dosing Period 1 (up to and including Visit 9, ie, Day 29).

Subject analysis set title	Placebo (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants received 3 doses of placebo in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Participants formed the Safety Set (SS) which consisted of all participants in the Randomized Set (RS) who had received at least 1 dose of investigational product (IMP).

Subject analysis set title	UCB7665 (7 mg/kg) (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Participants formed the Safety Set (SS) which consisted of all participants in the Randomized Set (RS) who had received at least 1 dose of investigational product (IMP).

Subject analysis set title	Placebo - UCB7665 (7 mg/kg) (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Subject analysis set title	Placebo - UCB7665 (4 mg/kg) (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Subject analysis set title	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Subject analysis set title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Primary: Change from Baseline in Quantitative Myasthenia Gravis (QMG) score to Visit 9

·	Change from Baseline in Quantitative Myasthenia Gravis (QMG) score to Visit 9

End point description:

The total QMG score was obtained by summing the responses to each individual item (13 items;

Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

End point type	Primary
End point timeframe:	
From Baseline to Visit 9 (up to Day 29)	

End point values	Placebo (FAS)	UCB7665 (7 mg/kg) (FAS)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	22	21	
Units: scores on a scale			
least squares mean (standard error)	-1.2 (± 0.6)	-1.8 (± 0.6)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Mixed Model Repeated Measures (MMRM) Analysis of Covariance (ANCOVA) model included fixed terms for treatment group, visit, interaction between treatment group and visit, covariate of Baseline QMG score, and random effect for participant.

The differences presented was 'UCB7665 (7 mg/kg) minus Placebo'.

Comparison groups	Placebo (FAS) v UCB7665 (7 mg/kg) (FAS)	
Number of subjects included in analysis	43	
Analysis specification	Pre-specified	
Analysis type	superiority	
P-value	= 0.221 [1]	
Method	MMRM	
Parameter estimate	LS Mean Difference vs Placebo	
Point estimate	-0.7	
Confidence interval		
level	95 %	
sides	1-sided	
upper limit	0.8	

Notes:

[1] - One-sided p-value was presented for difference.

Secondary: Change from Baseline in Myasthenia Gravis-Composite score to Visit 9

End point title	Change from Baseline in Myasthenia Gravis-Composite score to
	Visit 9

End point description:

The total Myasthenia Gravis (MG)-composite score was obtained by summing the responses to each individual item (10 items; Grade: 0-9 depending on item). The score ranges from 0 to 50, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

End point type	Secondary	
End point timeframe:		

From Baseline to Visit 9 (up to Day 29)

End point values	Placebo (FAS)	UCB7665 (7 mg/kg) (FAS)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	22	21	
Units: scores on a scale			
least squares mean (standard error)	-1.2 (± 0.9)	-3.1 (± 0.9)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

MMRM ANCOVA model included fixed terms for treatment group, visit, interaction between treatment group and visit, covariate of Baseline MG-composite score, and random effect for participant.

The differences presented was 'UCB7665 (7 mg/kg) minus Placebo'.

The differences presented was debroom (7 mg/kg) minus rideebo.		
Comparison groups	Placebo (FAS) v UCB7665 (7 mg/kg) (FAS)	
Number of subjects included in analysis 43		
Analysis specification	Pre-specified	
Analysis type	superiority	
P-value	= 0.089 [2]	
Method	MMRM	
Parameter estimate	LS Mean Difference vs Placebo	
Point estimate -1.8		
Confidence interval		
level	95 %	
sides	1-sided	
upper limit	0.4	

Notes:

[2] - One-sided p-value was presented for difference.

Secondary: Change from Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) score to Visit 9

End point title	Change from Baseline in Myasthenia Gravis-Activities of Daily
	Living (MGADL) score to Visit 9

End point description:

The total MGDAL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

End point type	Secondary
End point timeframe:	

From Baseline to Visit 9 (up to Day 29)

End point values	Placebo (FAS)	UCB7665 (7 mg/kg) (FAS)	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	22	21	
Units: scores on a scale			
least squares mean (standard error)	-0.4 (± 0.5)	-1.8 (± 0.5)	

Statistical analyses

Statistical analysis title Statistical analysis 1		
Statistical analysis description:		
ANCOVA model included fixed terms for treatment group, covariate of Baseline MGADL score.		
Comparison groups	Placebo (FAS) v UCB7665 (7 mg/kg) (FAS)	
Number of subjects included in analysis	43	
Analysis specification	Pre-specified	
Analysis type	superiority	
P-value	= 0.036 [3]	
Method	ANCOVA	
Parameter estimate	LS Mean Difference vs Placebo	
Point estimate	-1.4	
Confidence interval		
level	95 %	
sides	1-sided	
upper limit	-0.1	

Notes:

 $\label{eq:constraints} \mbox{[3] - One-sided p-value was presented for difference.}$

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the start of Treatment Period at Baseline and up to Observation Period at 8 weeks after the final dose of IMP.

7	Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

Reporting groups

Reporting group title	Placebo (SS)
-----------------------	--------------

Reporting group description:

Participants received 3 doses of placebo in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Participants formed the Safety Set (SS) which consisted of all participants in the Randomized Set (RS) who had received at least 1 dose of investigational product (IMP).

B # ###	110077775 (77 # 2 700)
Reporting group title	UCB7665 (7 mg/kg) (SS)

Reporting group description:

Participants received 3 doses of UCB7665 (7 mg/kg) in Dosing Period 1 and then were re-randomized into Dosing Period 2 to receive 3 doses of UCB7665 (7 mg/kg or 4 mg/kg). Participants formed the Safety Set (SS) which consisted of all participants in the Randomized Set (RS) who had received at least 1 dose of investigational product (IMP).

Reporting group title	Placebo - UCB7665 (7 mg/kg) (SS)
-----------------------	----------------------------------

Reporting group description:

Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Reporting group title	Placebo - UCB7665 (4 mg/kg) (SS)
-----------------------	----------------------------------

Reporting group description:

Participants randomized to receive 3 doses of placebo at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)
1 99 1	

Reporting group description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Reporting group title	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)
	. 6 6

Reporting group description:

Participants randomized to receive 3 doses of UCB7665 (7 mg/kg) at weekly intervals in Dosing Period 1 were then re-randomized to receive 3 doses of UCB7665 (4 mg/kg) at weekly intervals in Dosing Period 2. Participants formed the Safety Set (SS).

Serious adverse events	Placebo (SS)	UCB7665 (7 mg/kg) (SS)	Placebo - UCB7665 (7 mg/kg) (SS)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 22 (9.09%)	0 / 21 (0.00%)	3 / 11 (27.27%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	О	О

	•		
Injury, poisoning and procedural complications			
Ulna fracture			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0/0	0/0	0 / 1
deaths causally related to treatment / all	0/0	0/0	0/0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0/0	0/0	1 / 1
deaths causally related to treatment / all	0/0	0/0	0/0
Presyncope			
subjects affected / exposed	1 / 22 (4.55%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0
Myasthenia gravis			
subjects affected / exposed	1 / 22 (4.55%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 1	0/0	0 / 1
deaths causally related to treatment / all	0/0	0/0	0/0
Myasthenia gravis crisis			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0/0	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0

Serious adverse events	Placebo - UCB7665 (4 mg/kg) (SS)	UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)	UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Ulna fracture			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0/0	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0
Nervous system disorders			

I	I	1	ı
Headache			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0/0	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0
Presyncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0/0	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0
Myasthenia gravis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0 / 1	0/0	0/0
deaths causally related to treatment / all	0/0	0/0	0/0
Myasthenia gravis crisis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences causally related to treatment / all	0/0	0 / 1	0/0
deaths causally related to treatment / all	0/0	0/0	0/0

Frequency threshold for reporting non-serious adverse events: $5\ \%$

Non-serious adverse events	Placebo (SS)	UCB7665 (7 mg/kg) (SS)	Placebo - UCB7665 (7 mg/kg) (SS)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 22 (31.82%)	13 / 21 (61.90%)	7 / 11 (63.64%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	3 / 22 (13.64%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	4	О	1
Gait disturbance			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	3
Infusion site pruritus			

1		•	
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Infusion site swelling			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Asthenia Asthenia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)		·	
occurrences (all)	0	0	0
Inflammatory pain			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
		Ŭ	Ü
Infusion site reaction			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
		Ŭ	Ŭ
Laryngeal inflammation			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Orthopnoea			. ,
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Paranasal sinus discomfort			
1	1	I	1

subjects affected / exposed occurrences (all)	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
	0	0	1
	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
	0	0	0
	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
	0	0	0

subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders Anaemia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	О	О	0
Thrombooutoropio			
Thrombocytopenia subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
	Ü	Ü	Ü
Ear and labyrinth disorders Tinnitus			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
	<u> </u>		·
Eye disorders Diplopia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Eyelid ptosis subjects affected / exposed	0 / 00 / 0 00%	0 / 01 / 0 00%	1 (11 (0.00%)
occurrences (all)	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (an)	0	0	1
Keratitis			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	О	0	1
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 22 (9.09%)	3 / 21 (14.29%)	1 / 11 (9.09%)
occurrences (all)	2	3	1
Nausea			
subjects affected / exposed	0 / 22 (0.00%)	2 / 21 (9.52%)	0 / 11 (0.00%)
occurrences (all)	0	3	0
Vomiting			
Vomiting			

subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal pain subjects affected / exposed	0 / 22 (0 00%)	0 / 31 / 0 00%)	0 / 11 (0.00%)
occurrences (all)	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
	O	O	O
Cheilitis			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders Rash			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	О	0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Back pain			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	О
Limb discomfort			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
	_		-
Musculoskeletal pain			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	О
Pain in extremity			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	2
Arthralgia			
subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Groin pain			

subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 1 / 11 (9.09%) occurrences (all) 0 0 1 Muscle spasms 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 Musculoskeletal stiffness 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 / 21 (0.00%) 0 / 11 (0.00%) Infections and infestations 0 0 0 Upper respiratory tract infection 0 0 0
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 Musculoskeletal stiffness subjects affected / exposed occurrences (all) 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 0 0
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 Musculoskeletal stiffness subjects affected / exposed occurrences (all) 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 0 0
occurrences (all) Musculoskeletal stiffness subjects affected / exposed occurrences (all) O / 22 (0.00%) O / 21 (0.00%) O / 11 (0.00%) Infections and infestations
Musculoskeletal stiffness subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%) occurrences (all) 0 0 0 Infections and infestations 0 0 0
occurrences (all) 0 0 0
occurrences (all) 0 0
Infections and infestations
I Unner respiratory tract intection I I I I I I I I I I I I I I I I I I I
1
occurrences (all) 0 2 1
Cystitis
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 1 / 11 (9.09%)
occurrences (all) 0 2
Bronchitis
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%)
occurrences (all) 0 0
Nasopharyngitis
subjects affected / exposed 3 / 22 (13.64%) 0 / 21 (0.00%) 0 / 11 (0.00%)
occurrences (all) 3 0 0
Respiratory tract infection
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%)
occurrences (all) 0 0
Rhinitis subjects affected / exposed 0 / 22 (0 00%) 0 / 21 (0 00%) 0 / 11 (0 00%)
(1)
occurrences (all) 0 0
Urinary tract infection
subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%)
occurrences (all) 0 0
Metabolism and nutrition disorders
Fluid retention subjects affected / exposed 0 / 22 (0.00%) 0 / 21 (0.00%) 0 / 11 (0.00%)
occurrences (all) 0 0
Hypophosphataemia

subjects affected / exposed	0 / 22 (0.00%)	0 / 21 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1

Non-corious adverse avente	Placebo - UCB7665	UCB7665 (7 mg/kg)	UCB7665 (7 mg/kg)
Non-serious adverse events	(4 mg/kg) (SS)	- UCB7665 (7 mg/kg) (SS)	- UCB7665 (4 mg/kg) (SS)
Total subjects affected by non-serious adverse events		3. 3	3 3
subjects affected / exposed	9 / 11 (81.82%)	8 / 10 (80.00%)	9 / 10 (90.00%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions Fatigue			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)			
occurrences (an)	3	0	0
Gait disturbance			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infusion site pruritus			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)			
occurrences (an)	0	3	0
Infusion site swelling			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	2
, , , , , , , , , , , , , , , , , , ,			2
Pyrexia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
	·	_	
Asthenia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Inflammatory pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Infusion site reaction			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)			
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal			

			
disorders		ı	
Dyspnoea			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	3	1	0
Oropharyngeal pain			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	2	1	0
Dysphonia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Laryngeal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Orthopnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Stress			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Investigations			
Lymphocyte count decreased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications	1		
Injury corneal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Cardiac disorders			

Bundle branch block left subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1711 (9.09%)	0 7 10 (0.00%)	0 7 10 (0.00%)
Namuous sustana disandans			
Nervous system disorders Headache			
subjects affected / exposed	2 / 11 (18.18%)	4 / 10 (40.00%)	4 / 10 (40.00%)
occurrences (all)	2	5	6
Dizziness			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Myasthenic syndrome			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	1 / 10 (10.00%)
occurrences (all)	0	2	1
Dygarthria			
Dysarthria subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)			
occurrences (aii)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Paraesthesia Paraesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Diplopia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Eyelid ptosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	4 / 11 (36.36%)	1 / 10 (10.00%)	2 / 10 (20.00%)
occurrences (all)	4	1	2
Naves			
Nausea subjects affected / exposed	0 / 11 (0 00%)	1 / 10 /10 00%	2 / 10 / 20 00%)
occurrences (all)	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 10 (20.00%)
occurrences (aii)	0	2	2
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	0 / 10 (0.00%)
occurrences (all)	О	2	О
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
	·	, and the second	, and the second
Cheilitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue			
disorders Muscular weakness			
I Mascalar Weakiness	I	I	ı İ

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Book pain			
Back pain subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	1	1	0
	·	·	J
Limb discomfort subjects affected / exposed	0 /11 (0 00%)	1 / 10 / 10 000/)	0 /10 /0 00%
occurrences (all)	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (an)	0	2	0
Musculoskeletal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	1	0	1
Pain in extremity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Arthralgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Groin pain subjects affected / exposed	0 / 11 (0 00%)	0 / 10 (0 00%)	0 / 10 (0 00%)
occurrences (all)	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
			O
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	О	О	0
Bronchitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0

	1	1	
Nasopharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	О	О	1
Urinary tract infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Fluid retention			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 10 (10.00%)
occurrences (all)	О	О	1
Hypophosphataemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2017	Protocol Amendment 1 (dated 07 Feb 2017) was implemented to incorporate the feedback from the US Food and Drug administration (FDA) received on 09 December 2016 and the new company standard in tuberculosis (TB) management. Secondary efficacy variables and other efficacy variables were updated. In addition, minor administrative changes were made.
15 September 2017	Protocol Amendment 2 (dated 15 Sep 2017) was implemented to include an additional patient-reported outcome (PRO) assessment, intended as a measure of disease severity. This patient-centered index was developed for an outpatient setting and is sensitive to detect clinical change after interventions, and most importantly detect patient-meaningful change. Two additional other efficacy variables were added to capture changes for mean consecutive difference (MCD) and normal fiber pairs in jitter (single-fiber electromyogram [SFEMG]) studies to show the clinical trend from predose to postdose treatment. Furthermore, permitted concomitant medications were revised to include: modified and unmodified dose formulations for cyclosporin and increased dose strength for tacrolimus. With no specific dosing for tacrolimus, dosing is variable in patients with myasthenia gravis (MG), but for transplant related immunosuppression, higher doses are cited in literature; therefore, a slightly higher fixed dose was allowed. In addition, minor administrative and stylistic changes were made.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported